Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) EBITDA (2017 - 2025)

Crinetics Pharmaceuticals has reported EBITDA over the past 9 years, most recently at -$123.1 million for Q4 2025.

  • For Q4 2025, EBITDA fell 50.78% year-over-year to -$123.1 million; the TTM value through Dec 2025 reached -$464.4 million, down 55.62%, while the annual FY2025 figure was -$464.4 million, 55.62% down from the prior year.
  • EBITDA for Q4 2025 was -$123.1 million at Crinetics Pharmaceuticals, up from -$129.5 million in the prior quarter.
  • Over five years, EBITDA peaked at -$22.9 million in Q1 2021 and troughed at -$129.5 million in Q3 2025.
  • A 5-year average of -$62.4 million and a median of -$53.4 million in 2023 define the central range for EBITDA.
  • Biggest five-year swings in EBITDA: dropped 14.54% in 2023 and later plummeted 73.62% in 2025.
  • Year by year, EBITDA stood at -$31.2 million in 2021, then crashed by 40.91% to -$43.9 million in 2022, then plummeted by 32.66% to -$58.3 million in 2023, then plummeted by 40.19% to -$81.7 million in 2024, then tumbled by 50.78% to -$123.1 million in 2025.
  • Business Quant data shows EBITDA for CRNX at -$123.1 million in Q4 2025, -$129.5 million in Q3 2025, and -$116.0 million in Q2 2025.